Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a $17 price target.
June 25, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals and maintained a $17 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $17 price target by a reputable analyst suggests positive sentiment and confidence in Recursion Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100